Shareholders' General Extraordinary Meeting dated March 20, 2025 - Median Technologies

We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs.

With eyonis™ we are disrupting the management of serious diseases such as lung cancer and liver cancer. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. eyonis™ is currently under development.

Imaging Services for Clinical Trials

Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for biopharma sponsors worldwide.

10/02/2025

Notice of Shareholders’ General Extraordinary Meeting dated March 20, 2025 (in French only)

03/03/2025

Single voting form – Shareholders’ General Extraordinary Meeting dated March 20, 2025 (in French only)

03/03/2025

Extraordinary Resolutions – Shareholders’ General Extraordinary Meeting dated March 20, 2025

03/03/2025

Report of the Board of Directors on the Extraordinary Resolutions – Shareholders’ General Extraordinary Meeting dated March 20, 2025

03/03/2025

Resolution 1 (Rapport du commissaire aux comptes sur la modification envisagée du contrat d’émission des bons de souscription d’action BEI A) – Shareholders’ General Extraordinary Meeting dated March 20, 2025 (In French only)

03/03/2025

Resolutions 2 & 3 (Rapport du commissaire aux comptes sur l’émission d’actions et de diverses valeurs mobilières avec suppression du droit préférentiel de souscription) – Shareholders’ General Extraordinary Meeting dated March 20, 2025 (In French Only)

03/03/2025

Resolution 4 (Rapport du commissaire aux comptes sur l’augmentation du capital réservée aux adhérents d’un plan d’épargne d’entreprise) – Shareholders’ General Extraordinary Meeting dated March 20, 2025 (In French Only)